Urinary Tract InfectionsEBLSENCT06910878
Urinary Tract Infections Caused by Extended-spectrum Beta-lactamase-producing Enterobacteria
An observational study of Urinary Tract Infections, run by University Hospital, Strasbourg, France at 1 site in France.
Trial summary
Urinary tract infections (UTIs) are one of the most common pathologies encountered in general practice. However, with increasing bacterial resistance to antibiotics, their treatment is becoming increasingly complex. Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Urinary Tract Infections
- How many people
- 100 participants
- Where
- 1 siteFrance
- Study dates
- 24 Oct 2024to 24 Dec 2025
- Phase
- Observational
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Study population: Adult (≥18 years old) with an Enterobacteriaceae urinary tract infection treated in a primary care setting for urinary tract infection between June 1, 2024 and December 31, 2024
Who may be able to join
- Adult (≥18 years old)
- Subject with an Enterobacteriaceae urinary tract infection treated in a primary care setting for urinary tract infection between June 1, 2024 and December 31, 2024
- Subject not objecting, after being informed, to the reuse of their data for the purposes of this research.
- The subject's primary care physician agreeing to participate in the study
Who cannot join
- Subject and/or their primary care physician having expressed their opposition to participating in the study
- Subject under legal protection
- Subject under guardianship or curatorship
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
France1 site, 1 recruiting
- Recruiting
Service de maladies infectieuses et tropicales - Hôpitaux Universitaires de Strasbourg
Strasbourg
Yves HANSMANN, MD, PhD, 33 3 69 55 09 78, yves.hansmann@chru-strasbourg.fr
Yves HANSMANN, MD, PhD
About this study
Official title: Urinary Tract Infections Caused by Extended-spectrum Beta-lactamase-producing Enterobacteria: Management by General Practitioners in Bas-Rhin.
Urinary tract infections (UTIs) are one of the most common pathologies encountered in general practice. However, with increasing bacterial resistance to antibiotics, their treatment is becoming increasingly complex. Extended-spectrum beta-lactamase-producing Enterobacteriaceae (ESBL-E) pose a particular challenge due to their increased resistance to many commonly used antibiotics. The aim of this thesis is to study the management of such infections by general practitioners in Bas-Rhin and to suggest possible avenues for improvement.
- Conditions
- Urinary Tract Infections
- Keywords
- Urinary Tract Infections, Beta-Lactamase, Enterobacteriaceae
- Medical subject headings
- Urinary Tract Infections
What is being measured
The primary outcome is the main question the study is designed to answer.
Prescription rates of appropriate antibiotics for the treatment of ESBL-E UTIs
Prescription rates of appropriate antibiotics for the treatment of ESBL-E UTIs by general practitioners compared to current health authority recommendations
Measured: Up to 1 year
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted4 Apr 2025
- Study start24 Oct 2024
- Primary completion24 Dec 2025 (estimated)
- Study completion24 Dec 2025 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Urinary Tract InfectionsStudies of the same condition, open and under way.
- More trials run by University Hospital, Strasbourg, FranceThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Case only
- Time perspective
- Retrospective
- Enrolment
- 100 participants (estimated)
Sponsor and investigators
- Lead sponsor
- University Hospital, Strasbourg, France
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT06910878
- Sponsor's protocol ID
- 9307
- Acronym
- EBLSE
- Status last verified
- Mar 2025
- First submitted
- 28 Mar 2025
- Last updated
- 4 Apr 2025
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
Study at a glance
From the registry record, last updated by the sponsor on 4 Apr 2025. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Urinary Tract Infections Caused by Extended-spectrum Beta-lactamase-producing Enterobacteria: Management by General Practitioners in Bas-Rhin.
- ClinicalTrials.gov ID
- NCT06910878
- Acronym / sponsor ID
- EBLSE / 9307
- Conditions
- Urinary Tract Infections
- Keywords
- Urinary Tract Infections, Beta-Lactamase, Enterobacteriaceae
- Study type
- Observational
- Recruitment status
- Recruiting
- Enrolment
- 100 participants (estimated)
- Lead sponsor
- University Hospital, Strasbourg, FranceUniversity, hospital or other
- Study start
- 24 Oct 2024 (actual)
- Primary completion
- 24 Dec 2025 (estimated)
- Study completion
- 24 Dec 2025 (estimated)
- First posted
- 4 Apr 2025 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Urinary tract infections (UTIs) are one of the most common pathologies encountered in general practice. However, with increasing bacterial resistance to antibiotics, their treatment is becoming increasingly complex. Extended-spectrum beta-lactamase-producing Enterobacteriaceae (ESBL-E) pose a particular challenge due to their increased resistance to many commonly used antibiotics. The aim of this thesis is to study the management of such infections by general practitioners in Bas-Rhin and to suggest possible avenues for improvement.
Study design
- Observational model
- Case only
- Time perspective
- Retrospective
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
- Study population
- Adult (≥18 years old) with an Enterobacteriaceae urinary tract infection treated in a primary care setting for urinary tract infection between June 1, 2024 and December 31, 2024
Key inclusion criteria (4 listed)
- Adult (≥18 years old)
- Subject with an Enterobacteriaceae urinary tract infection treated in a primary care setting for urinary tract infection between June 1, 2024 and December 31, 2024
- Subject not objecting, after being informed, to the reuse of their data for the purposes of this research.
- The subject's primary care physician agreeing to participate in the study
Key exclusion criteria (3 listed)
- Subject and/or their primary care physician having expressed their opposition to participating in the study
- Subject under legal protection
- Subject under guardianship or curatorship
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Primary outcome
Prescription rates of appropriate antibiotics for the treatment of ESBL-E UTIs
Time frame: Up to 1 year
Prescription rates of appropriate antibiotics for the treatment of ESBL-E UTIs by general practitioners compared to current health authority recommendations
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 4 Apr 2025.
Related trials for Urinary Tract Infections
Recruiting
Diagnosis and Treatment of Urinary Tract Infection Using DNA Polymerase Chain Reaction Versus Urine Culture
Urinary Tract Infections
Active, not recruitingObservational study
Clinical Performance Evaluation of the QIAstat-Dx® cUTI Plus AMR
Complicated Urinary Tract Infection
Active, not recruitingPhase 1/2
A Beta-only IL-2 ImmunoTherapY Study
Advanced Solid Tumor, Unresectable Solid Tumor
Recruiting
INterest of the Negative Predictive Value of Integrons in the reduCtion of Large Broad-spectrum anTibiotics Consumption for Urinary Tract infectionS
Drug Resistance, Microbial, Biomarkers
Not yet recruitingObservational study
Comparative Study of the Genomic Characteristics of Uropathogenic Escherichia Coli According to the Severity of Community-Acquired Urinary Tract Infections in Guadeloupe (COLIGENURI)
Urinary Tract Infections
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Urinary Tract Infections, run by University Hospital, Strasbourg, France at 1 site in France.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 4 inclusion and 3 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 4 Apr 2025. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in France. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Yves HANSMANN, MD, PhD (33 3 69 55 09 78, yves.hansmann@chru-strasbourg.fr), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Prescription rates of appropriate antibiotics for the treatment of ESBL-E UTIs (time frame: Up to 1 year). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 4 Apr 2025.